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Age-related macular degeneration (AMD) is one of the main socioeconomical health issues worldwide. AMD has a multifactorial
etiology with a variety of risk factors. Smoking is themost important modifiable risk factor for AMDdevelopment and progression.
Thepresent review summarizes the epidemiological studies evaluating the association between smoking andAMD, themechanisms
throughwhich smoking induces damage to the chorioretinal tissues, and the relevance of advising patients to quit smoking for their
visual health.
1. Introduction
Age-related macular degeneration (AMD) is a macular neu-
rodegenerative disease that nowadays constitutes one of the
main socioeconomical health issues worldwide, afflicting the
elderly population. The exponentially increasing prevalence
of AMD is linked to progressive aging of the population, and
it is the leading cause of legal blindness in the developed
world [1–6]. It is traditionally divided into three categories:
early AMD, characterized by the presence of pigmentary
changes of the retinal pigment epithelium (RPE) and/or
hard small drusen; intermediate AMD, characterized by the
presence of soft large drusen and/or geographic atrophy (GA)
of the RPE with foveal sparing; and late AMD, characterized
by GA with foveal involvement and/or choroidal neovascu-
larization (CNV) [7, 8].
On the other hand, the presence or absence of CNV
makes the distinction between neovascular AMD (presence
of macular fluid and/or hemorrhage secondary to CNV) and
atrophic or nonneovascular AMD (presence of any other
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Table 1: Summary of the nonmodifiable and the modifiable risk
factors for age-related macular degeneration∗.
Nonmodifiable risk factors
Age
Gender
Iris color
Ethnicity
Hyperopia
Nuclear sclerosis
Family history of AMD
Complement factor H polymorphism
HTRA1 polymorphism
CX3CR1 polymorphism
Complement factors 2, 3 and B polymorphism
Modifiable risk factors
Smoking
Body mass index
Hypertension
Diabetes
Cholesterol
HDL-cholesterol
Acute myocardial infarction
Stroke
Angina
High alcohol intake
Dietary antioxidants and omega-3 fatty acids
Chronic renal failure
Hormone replacement therapy
Chlamydia pneumonie infection
Physical activity
Sunlight exposure
Cataract surgery
∗AMD: age-related macular degeneration; HTRA1: HtrA serine peptidase 1;
CX3CR1: CX3C chemokine receptor 1; HDL: high-density lipoprotein.
AMD sign except for CNV). Neovascular AMD accounts for
the most cases of severe vision loss, although the atrophic
form is the most frequent presentation of the disease [7–10].
A variety of risk factors for AMD have been described.
However, the evidence and strength of such associations are
widely variable, probably due to the difficulty of measuring
some of these factors in clinical practice [11, 12]. Advanced
age, Caucasian race, certain genetic polymorphisms, higher
body mass index, excessive alcohol consumption, and a
history of smoking are proven risk factors in the development
of AMD and progression to late AMD [13–19].
Risk factors may be classified as modifiable and nonmod-
ifiable (Table 1). They can also be divided depending on the
grade of evidence showed in the literature. Age showed the
highest evidence, as the odds ratio (OR) increases from 1 at
55–69 years to 4.42–8.70 at 70–79 years and 18.8–32.3 in ages
between 80 and 86 years [20–22]. Smoking (OR range: 2.39–
4.22) is the second most consistent risk factor related with
AMD [11, 23]. Race and ethnicity may also play an important
role, as the whites are the racial group with a higher risk
of AMD compared with the blacks or the Hispanic whites
[20–22]. Other significant risk factors are family history of
AMD (OR range: 3.95–6.98), previous cataract surgery (OR:
1.59), high body mass index (OR range: 1.06–1.35), and
hypertension (OR range: 1.02–1.48) [11, 23].
The purpose of this review is to analyze the current sci-
entific evidence of smoking as an independent risk factor in
AMD and the relevance of advising patients to quit smoking
for their visual health.
2. Material and Methods
A systematic review of all of the peer-reviewed articles
indexed in PubMed about smoking and age-related macular
degeneration was performed. The analyzed data were sum-
marized classifying them into four main headings: reported
epidemiological association between smoking and AMD;
studied mechanisms for toxic damage to the retina and
choroid induced by smoking; smoking and biomarkers in
AMD; and treatment considerations for AMD and smoking.
3. Results and Discussion
3.1. Epidemiological Association between Smoking and AMD.
Smoking is a major modifiable risk factor for AMD. The
association between smoking andAMDhas been consistently
demonstrated in many epidemiological studies carried out
within different populations in the last decades confirming
previous clinical impressions. Cross-sectional studies and
prospective cohort studies have described the natural history
of the disease and its associations with risk factors, where
smoking has been the most consistent factor associated with
geographic atrophy and neovascular AMD.
3.1.1. Cross-Sectional Studies. Cross-sectional studies exam-
ining the association between smoking andAMD include two
American, three European, and two large Australian popula-
tions. Further studies also provided additional information
about smoking as a risk factor for AMD in different ethnic
groups and geographic areas (Table 2). Population-based
epidemiologic studies have provided estimates of prevalence
and incidence of advancedAMDamong various racial/ethnic
groups: geographic atrophy and neovascular AMD are rare
before 55 years of age, becoming more prevalent in patients
aging over 75; overall, the prevalence is higher in Caucasian
and lower in African-American patients.
The Beaver Dam Eye Study recruited 4771 patients from
Beaver Dam (WI, USA) from 1988. After controlling subjects
for age and passive smoking, higher rates of neovascular
AMD in current-smokers compared to those who had never
smoked independently of gender were evidenced [24].
More recently, the study on the large Beaver Dam Off-
spring Study (BOSS) cohort found a prevalence of AMD of
3.4%. After controlling subjects for age and gender, a his-
tory of current-smoking and greater numbers of pack-years
smoked were associated with early AMD [25].
The Rotterdam Study is a single-center prospective
study of the population aging over 55 years in Rotterdam
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Table 2: Cross-sectional and prospective cohort studies examining the association between smoking and AMD: current-smokers versus
never-smokers∗.
Studies AMD types Odds ratio (95% CI)∗
Beaver Dam Eye Study
Early AMD
Neovascular AMD
Ever-smokers versus never-smokers:
M 1.29 (0.98–1.70)
F 1.02 (0.81–1.29)
Ever-smokers versus never-smokers:
M 2.86 (0.64–12.7)
F 2.06 (1.03–4.10)
Current-smokers versus never-smokers
or exsmokers:
M 3.29 (1.03–10.50)
F 2.50 (1.01–6.20)
Rotterdam Study
Atrophic AMD
Neovascular AMD
RR 1.5 (0.6–3.9), RR∗∗ 1.9 (0.7–5.4)
RR 3.6 (1.8–7.4), RR∗∗ 6.6 (2.8–15.9)
RR∼ 0.5 (0.1–4.5)
Blue Mountains Eye Study
Early AMD
All late AMD
Atrophic AMD
Neovascular AMD
1.89 (1.26–2.84)
4.46 (2.20–9.03)
4.94 (1.29–8.82)
3.26 (1.45–7.38)
Visual Impairment Project AMD 2.38 (0.83–6.80), 𝑃 = 0.11
Beaver Dam Offspring Study Early AMD 1.83 (1.06–3.17)
Age-Related Eye Disease Study (AREDS) Early AMD
Atrophic AMD
Neovascular AMD
Ever-smokers versus never-smokers:
1.25 (1.09–1.44), 𝑃 < 0.01
1.61 (1.06–2.42), 𝑃 < 0.05
1.91 (1.57–2.33), 𝑃 < 0.01
EUREYE Study Atrophic AMD
Neovascular AMD
Smoking in previous 25 years
2.27 (1.27–4.05)
2.86 (1.69–4.85)
Eye Disease Case-Control Study Group Neovascular AMD 2.20 (1.40–3.50), 𝑃 = 0.002
POLA Study Late AMD 3.6 (1.0–12.5)
Moon BG, 2012 Early AMD 1.53 (1.37–1.94), 𝑃 = 0.02
Cacket P, 2011 PCVNeovascular AMD
2.8 (1.4–5.5), 𝑃 = 0.002
4.3 (2.1–8.5), 𝑃 < 0.001
Prospective Cohort Study AMD types Relative risk (95% CI)∗
Physicians’ Health Study Neovascular AMD 2.10 (1.01–4.37), 𝑃 < 0.001
Nurses’ Health Study All AMD
Current smokers 1.70 (1.20-2.50),
Women who smoked 25 or more
cigarettes per day 2.4 (1.4-4.0),
𝑃 < 0.04
Beaver Dam Eye Study, 5 years
Early AMD
Progression of AMD
M 1.53 (0.81–2.99)
F 0.74 (0.40–1.35)
M 2.34 (1.00–5.44)
F 1.00 (0.50–2.01)
Beaver Dam Eye Study, 10 years
Early AMD
Late AMD
Progression of AMD
1.37 (0.98–1.94)
0.51 (0.18–1.46)
1.34 (0.94–1.91)
Blue Mountains Eye Study, 5 years
Geographic atrophy
Neovascular AMD
Any late AMD
3.6 (1.1–11.3)
1.6 (0.4–3.7)
2.5 (1.0–6.2)
Blue Mountains Eye Study, 10 years
Geographic atrophy
Neovascular AMD
Any late AMD
10.3 (2.7–39.1)
1.9 (0.6–5.3)
3.9 (1.7–8.8)
AREDS followup Geographic atrophy
1.82 (1.25–2.65)
1.55 (1.15–2.09)
Coleman AL, 2010 Early AMDLate AMD
OR 1.11 (0.53–1.23)
OR 1.04 (0.31–3.47)
∗AMD: age-related macular degeneration; ∗age and sex adjusted; ∗∗less than 85 years; ∼more than 85 years; CI: confidence interval; M: male; F: female; RR:
relative risk; POLA: Pathologies Oculaires Lie´es a` l’Age; PCV: polypoidal choroidal vasculopathy; OR: odds ratio.
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(The Netherlands). A total number of 6251 participants were
included from 1990 until 1993. Current- and former-smoking
was associated with an increased risk of neovascular AMD.
This increased risk was present up to 20 years after cessation
of smoking.This association was not present in persons aging
85 years and older [26].
The Blue Mountains Eye Study was conducted in Syd-
ney (Australia) between 1992 and 1994. A total number of
3654 patients were included. A highly significant association
between current-smokers and geographic atrophy and neo-
vascular AMD was evidenced [27]. Mitchell et al. estimated
that 20% of all cases of blindness in Australia may be
attributable to smoking, and they advocated a new warning
for cigarette packs about the risk of blindness associated with
smoking [28]. Later, the Visual Impairment Project (VIP)
included 4744 Australian patients and found that total dura-
tion of smoking (regardless of the amount) was significantly
associated with the prevalence of AMD, suggesting that 14%
of all AMDcasesmight be due to cigarette smoking for longer
than 40 years [29].
Pooled data from the aforementioned trials from three
different continents provided strong and consistent evidence
that tobacco smoking is the main known preventable expo-
sure associated with any form of AMD. Depending on the
type of AMD, current-smokers have 2- to 4-fold increase in
risk for AMD when compared to patients that never smoked
[30].
The Age-Related Eye Disease Study (AREDS) is a longi-
tudinal multicenter study of the natural history of AMD and
cataract in 4757 participants recruited between 1992 and 1998.
One of themain findings of the AREDSwas that smokingwas
associated with all of the threemore severe AMD groups [31].
The EUREYE Study is a cross-sectional study that
included 4,750 participants in 2003 from seven centers across
Europe. Current-smokers had increased odds of any type of
late AMD, and bilateral AMD was also more likely to have a
history of heavy smoking.The attributable fraction for AMD
due to smoking was 27%.
The Eye Disease Case-Control Study of risk factors for
neovascular AMD studied 421 cases and 615 controls between
1986 and 1990, finding a strong association between current
cigarette smoking and incidence of AMD [32].
The POLA (Pathologies Oculaires Lie´es a` l’Age) Study
included 2196 participants in France. Current- and former-
smokers were found to have an increased prevalence of late
AMD. This risk was higher in those patients who smoked 20
pack-years and more [33]. The odds ratio (OR) for current-
smokers and late AMD observed in this study (3.6) was
not significantly different from the OR of 4.46 in the Blue
Mountains Eye Study, the OR of 2.2 for neovascular AMD in
the Eye Disease Case-Control Study, the OR of 2.38 for late
AMD in the VIP Study, the OR of 3.6 for neovascular AMD
in the Rotterdam Study, and theORof 2.5 for women and 3.29
in men for neovascular AMD in the Beaver Dam Eye Study.
Other recent case-control studies show a significant asso-
ciation between both current- and former-smokers and early
AMD and polypoidal choroidal vasculopathy in Asian
patients [34, 35].
A novel population ofmonozygotic twins with discordant
phenotypes of AMD was studied. Smokers had a twice-fold
increased risk of AMD implicating that factors other than
DNA sequence are involved in the etiology of AMD.
3.1.2. Prospective Cohort Studies. Prospective cohort study
design is most suitable in order to demonstrate that smoking
precedes AMD development. There are three key cross-sec-
tional studies thatwere subsequently extended into longitudi-
nal studies.The length of the follow-up period is the strength
of two of them.
At 5-year followup, the Beaver Dam Eye Study reported
that men who smoked greater amounts of cigarettes were
more likely to develop early AMD. These results were con-
firmed over a 10-year followup and also evidenced that they
were more likely to have progression of the disease [36, 37].
The 5-year incidence of any late AMD lesions found in
current, past, or never-smokers in the Blue Mountains Eye
Study was 3.1%, 1.2%, and 1.4%, respectively. After adjusting
for age, current-smokers had an increased risk of incident
geographic atrophy (RR = 3.6; 95% CI: 1.1–11.3) and any
late lesions (RR = 2.5; 95% CI: 1.0–6.2) [38]. The long-term
incidence over 10 years showed that current-smokers had a
4-fold increase in the risk of late AMD compared with never-
smokers (RR = 3.9; 95% CI: 1.7–8.8). Former-smokers had a
3-fold higher risk of geographic atrophy (RR = 3.4; 95% CI:
1.2–9.7) [39]. A further pooled analysis of the 5-year results
from these three studies found a continued 3-fold association
of current-smoking with the development of AMD [23].
The Physicians’ Health Study [40] and the Nurses’ Health
Study [16] also evidenced that current-smokers of 20 or more
cigarettes per day had a 2-fold increased risk compared with
never-smokers in two different cohorts of incident cases of
AMD followed for at least 7 years.
The AREDS cohort with a median followup of 6.3 years
estimated that a larger amount smoked was statistically sig-
nificantly associatedwith the incidence of geographic atrophy
due to AMD [41]. More recently, Coleman et al. found an
increased risk of early AMD among subjects aging 80 years
or older who were smokers compared to those younger than
80 years who were not smokers [42].
The risk of smoking has also been estimated in a meta-
analysis from six prospective cohort studies, five case-control
studies, and five cross-sectional studies. Significant increases
in AMD risk were seen for current- versus never-smokers.
The odds ratio for case-control studies was 1.78 (95%CI: 1.52–
2.09), and it was 3.58 (95% CI: 2.68–4.79) for cross-sectional
studies. The relative risk (RR) obtained through analysis of
prospective cohort studies was 1.86 (95% CI: 1.27–2.73) [11].
Similar results were also found in a previous meta-analysis
[43].
3.1.3. Dose-Response Effect of Smoking. Several studies have
investigated the dose-response effect by comparing different
levels of smoking classified as pack-years, and most of them
confirmed a dose-response effect. The Rotterdam Study and
the POLAStudy found an increased risk of neovascular AMD
in persons who had smoked 10 or more pack-years (OR: 7.1,
95% CI: 2.10–19.0) and 20 or more pack-years (OR: 4.8, 95%
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CI: 1.80–12.9) [26, 33]. The Physicians’ Health Study and the
Nurses’ Health Study find significant 2-fold higher risk of
AMD in persons who had smoked more than 25 cigarettes
per day [16, 40]. The VIP Study results reveal that only the
duration, not the amount of smoking, is associatedwithAMD
[29]. In the 5-year follow-up results from the Beaver DamEye
Study the relative risk of early AMD and progression of early
AMD increased as the amount smoked increased [36]; the 10-
year follow-up results were inconsistent with earlier findings
from this and other studies, as no association of the amount
smoked or the incidence of late AMD was evidenced [37].
However, the Beaver Dam Offspring Study confirmed that
smoking 11 or more pack-years was associated with early
AMD [25]. Other studies in Korea and Japan also evidenced
that the level of smoking was associated with early and late
AMD [34, 44].
3.1.4. The Effect of Quitting Smoking. Exsmokers still have
an increased risk of developing AMD compared with never-
smokers. The Rotterdam Study was the first to reveal that
the increased risk of neovascular AMD remained present up
to 20 years after cessation of smoking [26], which was also
confirmed in the POLA Study [33].The Nurses’ Health Study
reported that past-smoker womenwho previously smoked 25
ormore cigarettes per day had a 2-fold increased risk of AMD
even 15 years after cessation of smoking [16]. Other prospec-
tive studies found that former-smokers compared with those
who never smoked had amodest increased risk of AMD [23].
3.2. Mechanisms for Toxic Damage to the Retina and Choroid
Induced by Smoking. Cigarette smoke is known to contain
an abundant number of toxic compounds. Some of them are
known to be either toxic or mutagenic [45]. Its pathological
effects through different biochemical pathways and an ocular
exposure to cigarette smoke may cause oxidative damage,
vascular changes, and inflammation within the pathogenic
cascade of AMD. Smoke is responsible for cellular changes
at the level of the RPE in AMD patients [46].
3.2.1. Angiogenesis and Neovascularization. Cigarette smoke
promotes pathophysiological processes that contribute to
atherosclerosis, including thrombosis, vascular inflamma-
tion, and endothelial dysregulation [47]. Nicotine itself
promotes angiogenesis in experimental models due to its
vasculogenic properties [48–50] and may also induce cate-
cholamine release increasing platelet aggregability. Platelets
contribute to the growth of plaque through the accretion of
thrombus, as well as through the release of growth factors
(such as platelet-derived growth factor (PDGF)) that induce
vascular smooth muscle cell proliferation. The effect of nico-
tine also enhances physiological angiogenesis, as observed
in wound healing [49, 51] where smoking is known to be a
risk factor to delay the wound healing process. In a murine
model of CNV, areas that underwent laser-induced rupture
of Bruch’s membrane are larger in mice after nicotine expo-
sure [51]. Human choroidal and retinal arterial endothelial
cells express nicotinic acetylcholine receptors (nAChR), and
nicotine enhances their proliferation, migration, and tube-
forming ability. Nicotine also exerts a vasoconstrictive action
via 𝛼-adrenergic stimulation which may impair blood flow
through the choroid [52].
Nornicotine, a metabolite of nicotine catalyses, can lead
to the accumulation of lipofuscin and, therefore, also con-
tribute to the formation of drusen in RPE. Nornicotine can
catalyze the alkene isomerization of key retinal intermediates
through iminium-ion formation and disrupt proper retinoid
homeostasis, revealing an underlying molecular mechanism
for tobacco-dependent pathologies, particularly AMD [53].
Cigarette smoke also contains dioxins that are present
primarily in the gaseous phase. Most of the toxic effects of
dioxins are mediated by the cytosolic dioxin receptor known
as aryl hydrocarbon receptor (AhR) [54, 55]. Dioxin acts on
ocular tissues through the AhR pathway, promotes vascular
endothelial growth factor (VEGF) production in mouse
retinal tissues and human RPE cells, and exacerbates the
development of laser-induced CNV in mice [56].
3.2.2. Oxidative Damage. The oxidative damage to the RPE
contributes to the development and progression of AMD, and
the alterations in the metabolic support of the RPE cause
apoptosis of the photoreceptors [57, 58]. Cigarette smoke
contains a large number of prooxidant compounds. Nicotine
promotes nitric oxide (NO) production, and the effect of
other proangiogenic growth factors [59]. Cadmium accumu-
lates preferentially in the RPE and choroid [60] andmay con-
tribute to the development of AMD through an increase in
reactive oxygen species (ROS).However, hydroquinone (HQ)
is the most abundant oxidant and is not only in cigarette
smoke but also in processed foods, plastic containers, and
atmospheric pollutants as well as its widespread occurrence
in nature [61, 62].
The RPE cells provide support for the structure and
function of the outer retina by secreting several cytokines
including monocyte chemoattractant protein-1 (MCP-1) [63,
64]. RPE cells after exposure to HQ can secrete MCP-
1 during inflammatory responses promoting macrophage
dysfunction.MCP-1 expression ismarkedly decreased in RPE
cells in smoker AMDpatients andmight play a key role in the
pathogenesis of AMD [65, 66]. Both in vitro and in vivo find-
ings suggest that HQ-induced oxidative damage is unequiv-
ocally associated with an imbalance between VEGF and
PEDF [65] leading to pathological angiogenesis for the devel-
opment of CNV [67]. RPE cells from smoker AMD patients
exhibit VEGF expression increase and PEDF expression
decrease [65–67].
The exposure to cigarette smoke and HQ results in
RPE membrane blebbing and sub-RPE deposits in mice.
In cultured RPE cells, HQ-induced oxidative injury results
in reorganization of actin cytoskeleton and blebs formation
important for accumulation of deposits [65–67]. After expo-
sure to HQ, phosphorylate heat shock protein 27 (Hsp27)
expression increases, and there is an F-actin reorganization
required for RPE-derived bleb formation [65]. Therefore,
phosphorylated Hsp27 might be a key mediator in AMD.
Cigarette smoke extract (CSE) is widely used for in vitro
models [68–70]. CSE causes oxidative damage to human
RPE cells in vitro, cell death, significantly reduces viability
in both ARPE-19 cells and primary RPE cells, via alterations
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in mitochondrial integrity, and increases lipid peroxidation
[71]. Lower concentrations of CSE may induce ROS release
and thus cause oxidative stress in primary human RPE
cells. Treatment of primary human RPE cultures with CSE
could significantly increase the proportion of 𝛽-galactosidase
(SA-𝛽-Gal) cells [72]. Sublethal concentrations of hydrogen
peroxide have been shown to induce senescence associated
to SA-𝛽-Gal activity in primary cultured RPE cells [73] and
in vivo in RPE cells of old primate eyes [74].
Other molecules are involved in oxidative damage. Expo-
sure of primary human RPE cells to CSE may also lead
to significant elevations of Apo J, CTGF, and fibronectin
expression, which are senescence-associated biomarkers [71].
All three biomarkers are inducible by oxidative stress [75, 76]
and have been previously detected in the RPE of AMD
donor eyes, although its role and function in the RPE remain
unclear.
Oxidative stress is thought to be essential in lipofuscin
and drusen formation [77, 78]. Acrolein, an unsaturated
aldehyde found in the gas phase of cigarette smoke, exerts an
oxidant-mediated damage by inducing proteinmodifications.
RPE cells exposed to acrolein show a decrease in viability and
mitochondrial membrane potential due to oxidative stress
[79]. In the acrolein RPEmodel, there is a significant decrease
in mitochondrial membrane potential, oxygen consumption,
and activity of mitochondrial complexes, and it increased
significantly the calcium-ion level [80].
3.2.3. Toxicity. Polycyclic aromatic hydrocarbons (PAHs) are
one of the most toxic compounds in cigarette smoke [81].
They form DNA adducts. Benzo(a)pyrene (B(a)P) is a PAH
with toxic effects on cultured RPE and RPE/choroid from
bovine exposed to chronic cigarette smoke. It causes extensive
mitochondrialDNAdamage and increases lysosomal activity,
formation of a reactive epoxide [82], and caspase-mediated
cell apoptosis of human RPE cells [83] perhaps through the
generation of epoxides.These altered cell biological processes
in the RPEmay contribute to the formation of drusen in indi-
viduals who are cigarette smokers and underlie susceptibility
to genetic mutations associated with AMD.
3.2.4. Experimental Models. ARPE-19 cells, a spontaneously
arising human RPE cell line [84], are widely used for in vitro
studies of cigarette smoke effect in RPE cells. These cells are
treated with different toxic substances derived from cigarette
smoke such as HQ [85], acrolein [79, 85], CSE [71, 72], B(a)P
[86], cadmium [60], and 2,3,7,8-tetrachlorodibenzo-p-dioxin
(TCDD) [56]. Recently, the effect of the HQ has been studied
in a combination of three cellular lines: ARPE-19 cells, rat
retinal neurosensory cells (R-28), and human microvascular
cells (HMVEC), to demonstrate that nonapoptotic cell death
can occur inmany forms after the damage [85].Humandonor
eyes obtained from the eye bank are processed to obtain
human RPE cells. These cellular lines are exposed to HQ [65]
and CSE [72] to demonstrate a decrease in the viability after
damage. On the other hand, bovine RPE cells also are used
in in vitro experiments to study the effect of exogenous B(a)P
[82]. Other types of experiments include RPE/choroids from
mice to analyze the treatment of HQ [56, 65].
3.2.5. In Vivo Animal Models. As in in vitromodels, the same
toxic compounds are used in animals to investigate the effect
of cigarette smoke in the retina. C57BL/6-pigmented mice
are the most widely used in the literature. Hence, these mice
receive HQ orally in drinking water for a period of time
[65] and are injected intraperitoneally with TCDD [56]. On
the other hand, mice are placed into a smoking chamber
for a period of time to analyze the effect of the CSE. This
chamber contains a smokingmachine in differentmodels that
burns some cigarettes. Control mice are kept in a filtered-
air environment [66, 86, 87]. Cigarette smoke has been also
studied in RPE sheets from rats exposed to nicotine in
drinking water [65].
3.2.6. Histopathological Changes. The RPE constitutes a cell
monolayer that is crucial tomaintain a normal photoreceptor
function. RPE cell apoptosis and basal deposits, or accumu-
lations of heterogeneous debris in Bruch’s membrane, are two
critical histopathologic changes that are well recognized to
occur during the development of early AMD [88]. Fujihara
et al. observed these changes in mice after chronic exposure
to cigarette smoke [87], and Espinosa-Heidmann showed
that shorter duration and higher concentration of cigarette
smoke in old mice induce ultrastructural changes to Bruch’s
membrane and the choriocapillaris endothelium that are
compatible with early AMD [87].
In summary, the most important alterations observed
are Bruch’s membrane thickening, mild basal deposits and
enlargement, and loss of basolateral infoldings, which are an
established marker of epithelial cell injury. The formation of
vacuoles is a second sign of RPE damage.
4. Biomarkers and Smoking in AMD
In order to look for the most appropriate therapies and to
individualize lifestyle recommendations, it is ideally neces-
sary to integrate the different clinical features, the habits, and,
if available, the biomarkers of a certain disease. A biomarker
is a characteristic objectivelymeasured and evaluated as indi-
cator of physiologic/pathologic processes or pharmacologic
responses.
Different biomarkers have been studied in AMD patients
[89–91]. However, very limited information exists about
biomarkers in smokers and type, stage, and progression
of AMD or clinical response to treatment. Seddon et al.
evaluated the association of serum C-reactive protein (CRP)
levels and the risk of AMD, showing that in the smoking
population this risk was increased more than 1.7-fold in the
lower PCR levels (CRP < 4.5mg/L).There was no association
between smoking and AMD in the highest level of CRP
(CRP > 4.5mg/L). However, the CRP levels were significantly
higher among participants with advanced AMD (case
patients) than among those with no AMD (controls; median
values: 3.4 versus 2.7mg/L; 𝑃 = .02), so the highest levels of
CRP seem to increase the risk of AMD independently of
smoking [92].
In a subsequent study, Seddon et al. found that smok-
ing had a positive association with some proinflammatory
cardiovascular disease biomarkers such as CRP, interleukin
Journal of Ophthalmology 7
6, soluble tumor necrosis factor alpha receptor 2, soluble
intercellular adhesionmolecule-1 (ICAM-1), and apolipopro-
tein B (ApoB) but not with vascular cell adhesion molecule-1
(VCAM-1) or lipoprotein(a) in nonexudative AMD [93].
Gibson et al. assessed the levels of plasmatic complement
component C1 inhibitor (C1inh), and they found that C1inh
levels were higher in smokers compared to nonsmokers
[94]. These results highlight the importance of considering
smoking status in AMD populations.
Other biomarkers have been studied separately in smok-
ers versus nonsmokers and AMD patients versus normal
patients and a parallel increase (e.g., increased levels of lipid
peroxidation products) and decrease (e.g., decreased levels of
antioxidants) of considered markers have been found in both
kinds of studies [89, 94–98].
5. Treatment Considerations for
AMD Smoking Patients
There is limited information about the specific treatment of
dry and wet AMD in smokers.The use of antioxidant supple-
mentation consisting of vitamin C (500mg), vitamin E (400
international units), beta-carotene (15mg), zinc (80mg),
and copper (2mg) demonstrated reduction of the risk of
progression to advanced dry AMD in the AREDS Study with
an average followup of 6.3 years. Some evidence suggested
that smokers taking beta-carotene supplementation had an
increased risk of lung cancer [99, 100]. However, at the end of
the study, the influence of treatment onmortality stratified by
smoking status found no effect for current-smokers who took
antioxidants. Otherwise, the small proportion of deaths from
lung cancer (0.8%) in the AREDS Study showed no difference
between treatments [101].
More recently, the AREDS2 Study showed that the addi-
tion of omega-3 fatty acids and/or lutein+zeaxanthin to the
the original AREDS formulation only reduces by 10% the risk
of progression to advanced dry AMD or neovascular AMD
[102]. Moreover, there was no effect of beta-carotene elimi-
nation or lower zinc dose to the original AREDS formulation
on progression to advanced AMD. Given the hypothetic
risk of lung cancer due to beta-carotene supplementation,
current- or former-smokers within the past year were allowed
to participate in the study only in the groups not receiving
beta-carotene. The incidence of lung cancer was higher in
the beta-carotene (2%) group than in the non-beta-carotene
group (0.9%), mainly in former-smokers (91% of partici-
pants who developed lung cancer were former-smokers).
The simultaneous administration of high doses of beta-
carotene and lutein+zeaxanthin may suppress serum and
tissue levels of lutein+zeaxanthin due to the competitive
absorption of carotenoids.TheAREDS2 Study concluded that
lutein+zeaxanthin could be a safe carotenoid substitute in the
AREDS formulation [102].
In addition, the influence of smoking on the visual out-
comes in cases of neovascular AMD treated with intravitreal
vascular endothelial growth factor inhibitors has also been
analyzed. Lee et al. evidenced that smokers had a statistically
significant higher risk (7-fold increase) for a poor response
to intravitreal therapies [103], whereas other authors found
better functional outcomes in nonsmokers compared with
smokers but without statistical significance [104]. The mech-
anism for the negative influence of cigarette smoking in the
response to these therapies is poorly understood.
6. Conclusions
Age-related macular degeneration (AMD) is the commonest
cause of irreversible visual loss in the Western World [1–6].
AMD is a complex multifactorial disease with an uncertain
etiology associated with genetic and environmental risk fac-
tors.The hypothesis that interventions trying tominimize the
role of such environmental factors may reduce the incidence
ofAMDand/or the progression to late stages has led to several
studies evaluating their relevance in the clinical practice.
Among them, cigarette smoking is a proven risk factor for
both development and progression of AMD [24–43], as well
as for the clinical response in both atrophic and neovascular
forms of AMD [99–104]. As has been previously described,
smoking by itself promotes molecular and pathological
changes that may establish an ideal macular microenviron-
ment for the development of AMD: vascular inflammation
and endothelial dysregulation [47–56], oxidative damage
[57–80], toxic damage, and histopathological changes [81–
87]. However, patients are not frequently aware of the signifi-
cant role played by cigarette smoking in blindness associated
with AMD. Sometimes, even physicians forget about advising
patients of the relevance to quit smoking. Quitting smoking
reduces the risk of AMD, and after 20 years of cessation
the risk of developing AMD is the same as for nonsmokers
[105, 106].
Recently, genetic testing has arisen as an option to provide
patients with a certain risk profile based on their own genetic
phenotypes in the high-risk genes for AMD [106–108]. This
is even more relevant in smoking subjects, as a genetic high-
risk profile might influence their motivation to quit smoking
[106].
In the situation described above, we believe that institu-
tional support to disseminate the relevance of cigarette smok-
ing in terms of visual health is warranted. Very few coun-
tries show health warnings on cigarette packets related to
this issue (“SMOKING CAUSES BLINDNESS”), whereas
several other health issues warnings are usually included.
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